Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Paper

Abstract

A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes - infusions into the resected tumor cavity followed by infusions into the ventricular system. Intracranial infusions of IL13Rα2-targeted CAR T cells were not associated with any toxic effects of grade 3 or higher. After CAR T-cell treatment, regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. This clinical response continued for 7.5 months after the initiation of CAR T-cell therapy. (Funded by Gateway for Cancer Research and others; ClinicalTrials.gov number, NCT02208362.).

Analysis

Paper intelligence

Summary

This case study reports the regression of recurrent glioblastoma in a patient treated with IL13Rα2-targeted CAR T-cell therapy delivered via intracranial infusions.

Key findings

Multiple intracranial infusions of IL13Rα2-targeted CAR T cells were administered over 220 days.
No toxic effects of grade 3 or higher were observed.
Complete regression of all intracranial and spinal tumors was observed.
Increased levels of cytokines and immune cells in cerebrospinal fluid correlated with tumor regression.

Methods

Administration of chimeric antigen receptor (CAR)-engineered T cells targeting IL13Rα2.
Multiple infusions over 220 days.
Intracranial delivery routes: resected tumor cavity and ventricular system.
Monitoring of tumor response, toxicity, and cerebrospinal fluid cytokine/immune cell levels.

Limitations

Single patient case study.
Specific to recurrent multifocal glioblastoma.
Limited follow-up duration mentioned (7.5 months of response).

Applications

Treatment of recurrent glioblastoma.
Potential for engineered T-cell therapy in solid tumors.

Confidence100%

Discovery

Related papers

2027PubMed

Nucleofection-Based CRISPR/Cas Delivery in Human T Cells for Immunotherapy Applications.

Ortiz-Bueno M; Millán-López A; Labun K; Benabdellah K

Jan 1, 2027Methods in molecular biology (Clifton, N.J.)

2027PubMed

Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer.

Wu T; Lv B; Wang H; He G; Fu Y; Ji X; Zeng Y; Ni D; Qiu J; Hua K

Jan 1, 2027Bioactive materials

2026arXiv

Combining standard chemoradiotherapy with CAR-T cell therapy in malignant gliomas: Insights from an impulsive mathematical framework and virtual trials

Dmitry Sinelshchikov; Nikols Amaru Mora Millán; Miguel Perales-Patón; Juan Belmonte-Beitia; Matteo Italia

Sep 30, 2026

2026Crossref1 citations

From monolayer to organoids and multi-organ microphysiological systems: advancing regenerative medicine and precision therapies

Mahmood S. Choudhery; Ahmad Niaz; Taqdees Arif; Ruhma Mahmood

Jul 2, 2026Stem Cell Research & Therapy

2026Crossref0 citations

CAR-Mix cell therapies to treat solid tumors by providing synergistic interaction between engineered macrophages and polyclonal T cells.

Xudong Wang; Jin Zhang

Jun 1, 2026Journal of Clinical Oncology

2026Crossref0 citations

Intraosseous therapy: harnessing the potential of tissue regeneration and repair

Mikhail Yu. Artamonov; Inessa A. Minenko

May 8, 2026Frontiers in Medicine

Source record

Publication metadata

Authors: Christine E. Brown; Darya Alizadeh; Renate Starr; Lihong Weng; Jamie R. Wagner; Araceli Naranjo; Julie R. Ostberg; M. Suzette Blanchard; Julie Kilpatrick; Jennifer Simpson; Anita Kurien; Saul J. Priceman; Xiuli Wang; Todd L. Harshbarger; Massimo D’Apuzzo; Julie A. Ressler; Michael C. Jensen; Michael E. Barish; Mike Y. Chen; Jana Portnow; Stephen J. Forman; Behnam Badie
Published: Dec 28, 2016
Journal or venue: New England Journal of Medicine
DOI: 10.1056/nejmoa1610497
Paper type: journal article
Source: Openalex

DOI OpenAlex